Transforming ALS Diagnosis and Drug Discovery
Breakthrough diagnosis and treatments
—reimagining ALS care with cutting-edge technology.
About SONoALS
Mission-Driven Science
SONoALS, Inc. is a pioneering startup to redefine how ALS is diagnosed and treated. Our mission is to bring non-invasive, data-rich monitoring to the frontlines of neurodegenerative disease research. The team unites clinical neuroscience and biomedical engineering to make that mission a reality.
Breakthrough Technology
Wearable Ultrasound × AI-Powered Analysis
Revolutionary ultrasound technology combined with AI-powered analysis for Amyotrophic Lateral Sclerosis (ALS) monitoring and diagnosis.
Precision Tools for ALS Research and Beyond
Transforming healthcare through innovative applications in early diagnosis and drug discovery.
Applications
Early and Non-invasive Diagnosis of ALS
- Fasciculations are one of the biomarkers that appear earlier than needle EMG abnormalities.
Drug Discovery Support
Fasciculation biomarkers responding in days
- Pre-clinical drug screening in humans
- Selection of responder groups
- Significant reduction in clinical trial duration
- Personalized medicine
We aim to realize these goals.
News & Press
Latest updates and achievements from SONoALS
Notice of New Product Addition to "INDICATE: Bridging Diagnosis and Treatment Support"
Dec 5, 2025
ALS-related Technology using Wearable Ultrasound and AI (FasScan)
Patent filed: Diagnostic and therapy technology using ultrasound
Nov 17, 2025
Domestic patent application filed (JP 2025-196949)
Selected for MEDISO Accompanied Support Program (MHLW)
Nov 6, 2025
Selected for the MEDISO accompanied support program by Japan's Ministry of Health, Labour and Welfare
Get in Touch
Ready to learn more about our revolutionary ALS technology? Let's connect.
Company Information
Address
WALLSQUARE Kitanozaka
2-13-15 Yamamoto Ave., Chuo Ward
Kobe City, Hyogo 650-0003, Japan
chizu@sonoals.com
Established
May 2025
Tadashi Kojima
COO, SONoALS